Health Care · Pharmaceutical Preparations

AUPH Aurinia Pharmaceuticals Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 160062080 filings
Russell 2000

AUPH at a glance

Aurinia Pharmaceuticals Inc. (AUPH, SEC CIK 1600620) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $283.1 million (up 20.4% from FY2024) and net income of $287.2 million. Diluted EPS was $2.07.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Aurinia Pharmaceuticals Inc. (AUPH) shares worth $502.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Robertson Stephen P. on November 13, 2026 of 11,867 shares at $15.97 per share.
  • In the last 90 days, AUPH insiders reported 0 open-market purchases ($0) and 2 open-market sales ($380K) on Form 4, a net sale of $380K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$283.1M
+20.4% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$380K
13F holders
26 funds
$502.9M · −2 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Development and commercialization of LUPKYNIS, an immunosuppressant drug, plus pipeline advancement of aritinercept
  • Emphasis on aritinercept clinical development with noted risks of delays, effectiveness, and regulatory approval uncertainty
  • Strategic focus this year on patent litigation defense against generic competition, involving paragraph IV ANDA notices and infringement lawsuits
  • Notable quantitative metric: U.S. patents for LUPKYNIS extended through December 2037; ongoing significant patent litigation costs expected
  • Most noteworthy fact: Increased risk exposure due to patent law changes under Leahy-Smith America Invents Act affecting patent protection and litigation dynamics

Risk Factors

  • Regulatory risk: Failure to comply with Medicaid Drug Rebate Program reporting may trigger CMS penalties, FCA allegations, and potential termination risking U.S. reimbursement for LUPKYNIS
  • Geopolitical risk: Reliance on Otsuka for commercialization and supply in the Otsuka Territories; failure by either party may limit LUPKYNIS sales in these ex-U.S. markets
  • Operational risk: Dependence on Lonza contract manufacturing for LUPKYNIS supply, with shared facility capacity posing production and delivery vulnerabilities
  • Competitive risk: LUPKYNIS faces competition from BENLYSTA, GAZYVA, and off-label regimens including tacrolimus, limiting growth potential amid entrenched treatment practices
  • Financial risk: High commercial expenditures to maintain sales/marketing capabilities for LUPKYNIS sales growth increase cost structure and business risk

Management Discussion & Analysis

  • Revenue $283.1M, up 20% YoY; Net product sales $271.3M up 25%, License revenue $11.7M down 38%
  • Gross margin stable at 88%; Operating expenses $178.1M down 26% from $239.8M; Operating income $104.9M vs loss $4.7M
  • Best segment: Net product sales $271.3M up $55.2M; worst: License, collaboration $11.7M down $7.2M
  • Cash $398.0M, up $39.5M; Operating cash flow $135.7M vs $44.4M; Share repurchases $98.2M, no dividend disclosed
  • 2026 SG&A expected flat at ~$101.8M; R&D to increase; Risks from market penetration and raising capital if needed

AI summary of the AUPH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $83.7M, up 14% YoY from $73.5M, driven by LUPKYNIS sales
  • Gross margin 90% vs 89% YoY, net income $31.7M vs $31.6M
  • LUPKYNIS sales $79.4M, up 12% YoY from $70.6M
  • Cash, restricted cash and investments $486.9M vs $398.0M at December 31, 2025
  • Operating cash flow $131.5M, up 46% YoY; share repurchases $74.9M for 5.0M shares

Risk Factors

  • No material risk-factor changes since the December 31, 2025 Form 10-K
  • Carried-forward financial-performance risks could cause actual results to differ materially from expectations
  • Additional currently immaterial or unknown risks could materially affect future results

AI summary of the AUPH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $83.7M, up 14%; nine-month revenue $244.6M, up 19%, led by LUPKYNIS sales
  • Nine-month net income $103.5M, up 35%, with operating cash flow $131.5M, up 46%

Item 2.02: Results of Operations and Financial Condition

  • Aurinia announced financial results for the three months ended September 30, 2026
  • Exhibit 99.1 contains the detailed quarterly financial results for investor review
Filed Aug 19, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Teva patent settlement removes litigation uncertainty over generic 7.9 mg voclosporin capsules
  • Teva acknowledged Aurinia patents valid, enforceable, and infringed by U.S. commercial sales

Item 8.01: Other Events

  • Settlement resolves Teva patent litigation over generic 7.9 mg voclosporin capsules in the United States
  • Generic-entry timing and launch restrictions depend on settlement terms in Exhibit 99.1
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $83.2M, up 19%; LUPKYNIS sales $79.4M, confirming continued commercial momentum
  • Six-month net income $71.8M, up 60%; diluted EPS $0.53 versus $0.32

Item 2.02: Results of Operations and Financial Condition

  • Aurinia announced financial results for the quarter ended June 30, 2026
  • Full operating metrics and management commentary are contained in Exhibit 99.1

AI summaries of AUPH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AUPH

Don't miss the next AUPH filing

  • Alerts as it files. A push when AUPH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AUPH, by share count.
  • Ask anything. An AI agent that reads every AUPH filing and answers with sources.

AUPH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Robertson Stephen P.SellNov 13, 2026$15.97
Robertson Stephen P.SellSep 10, 2026$15.95
Robertson Stephen P.SellAug 21, 2026$16.97
Bailey Jeffrey AllenAJun 4, 2026-
Nova Tina SusanAJun 4, 2026-
Goetz KathleenAJun 4, 2026-
Johnson Craig AAJun 4, 2026-
Hearne Michael SAMay 18, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$175.5M$235.1M$283.1M
Operating Income-$91.7M-$4.7M$104.9M
Net Income-$78.0M$5.8M$287.2M
Op. Margin-52.2%-2.0%37.1%
Net Margin-44.5%2.4%101.5%
Balance Sheet
Total Assets-$550.6M$751.6M
Equity$378.0M$377.5M$581.3M
ROE-20.6%1.5%49.4%
Per Share
EPS$-0.54$0.04$2.07
Cash Flow
Operating CF-$33.5M$44.4M$135.7M

Source: XBRL data in Aurinia Pharmaceuticals Inc. (AUPH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AUPH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AUPH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$502.9M
Q2 202628$543.3M
Q1 202628$403.2M
Q4 202527$409.6M
Q3 202528$260.1M
Q2 202528$177.7M
Q1 202526$116.4M
Q4 202420$81.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AUPH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
10-QOct 30, 2026Analysis
8-KOct 30, 2026Analysis-
4Sep 11, 2026--
4Aug 25, 2026--
8-KAug 19, 2026Analysis-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 4, 2026Analysis
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
8-KMay 11, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
8-KApr 3, 2026Analysis-
8-KMar 23, 2026--
4Mar 10, 2026--
4Mar 3, 2026--
4Mar 3, 2026--
4Mar 3, 2026--

Related Health Care companies

All Health Care →

AUPH SEC filings: frequently asked questions

Are AUPH insiders buying or selling?

In the last 90 days, Aurinia Pharmaceuticals Inc. (AUPH) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $379,943 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold AUPH stock?

As of September 30, 2026, the largest Aurinia Pharmaceuticals Inc. (AUPH) holders among the 13F filers tracked by SignalX were BlackRock ($139.0 million), Goldman Sachs Group ($102.7 million), Two Sigma Investments ($47.8 million), State Street Corp ($42.0 million), Morgan Stanley ($29.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AUPH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $283.1 million (up 20.4% from FY2024) and net income of $287.2 million. Diluted EPS was $2.07. The figures come from the XBRL data in the 10-K.

What are the main risks in AUPH's latest 10-K?

In the 10-K filed February 26, 2026, Aurinia Pharmaceuticals Inc. (AUPH) flagged: Regulatory risk: Failure to comply with Medicaid Drug Rebate Program reporting may trigger CMS penalties, FCA allegations, and potential termination risking U.S. reimbursement for LUPKYNIS. Geopolitical risk: Reliance on Otsuka for commercialization and supply in the Otsuka Territories; failure by either party may limit LUPKYNIS sales in these ex-U.S. markets. (AI summary of the Risk Factors section.)

What did AUPH report in its latest 8-K?

Aurinia Pharmaceuticals Inc. (AUPH) filed an 8-K on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $83.7M, up 14%; nine-month revenue $244.6M, up 19%, led by LUPKYNIS sales.

What are the latest AUPH SEC filings?

Aurinia Pharmaceuticals Inc. (AUPH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 16, 2026.

What is AUPH's SEC CIK number?

Aurinia Pharmaceuticals Inc. (AUPH)'s SEC Central Index Key (CIK) is 1600620. EDGAR lists every AUPH filing under that number.

Ask anything about AUPH

The research agent reads AUPH's filings, financials, insider trades and 13F holders, then answers with sources.